drugset / Trial / NCT04035135
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
Phase 1
Completed
14 enrolled
Annexon, Inc.
International Centre for Diarrhoeal Disease Research, Bangladesh · collabResearchPoint Global · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.
Timeline
- Start
- 2020-01-29
- Primary completion
- 2021-05-19
- Completion
- 2021-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANX005 | Protein / enzyme biologic | 75 mg/kg | Intravenous |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 0.4 g/kg | Intravenous |